Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Langdahl

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Acta Orthopaedica Scandinavica. Supplementum|October 1, 1995
Bone changes in metabolic bone diseaseE F Eriksen, B Langdahl
Bone|November 1, 1996
European and North American Experience with HRT for the prevention of osteoporosisE F Eriksen, M Kassem, B Langdahl
European Journal of Clinical Investigation|July 1, 1996
Growth hormone, insulin-like growth factors and bone remodellingE F Eriksen, M Kassem, B Langdahl
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 19, 2019
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosisA S Koldkjær Sølling, T Harsløf, B Langdahl
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 24, 2019
Glucagon-like peptide-1 receptor agonists and fracture risk-limitations to current knowledgeK Hygum, T Harsløf, B Langdahl, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 26, 2022
Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates-a real-world cohort studyJ Starup-Linde, B Langdahl, P Vestergaard, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 31, 2021
The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA studyA S Sølling, T Harsløf, N H Bruun, et al.
Kidney International|September 1, 1999
Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failureM Rix, H Andreassen, P Eskildsen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 15, 1999
Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal womenE F Eriksen, B Langdahl, A Vesterby, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 22, 2016
Hypercalcemia after discontinuation of long-term denosumab treatmentA S Koldkjær Sølling, T Harsløf, A Kaal, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Acta Orthopaedica Scandinavica. Supplementum|October 1, 1995
Bone changes in metabolic bone diseaseE F Eriksen, B Langdahl
Bone|November 1, 1996
European and North American Experience with HRT for the prevention of osteoporosisE F Eriksen, M Kassem, B Langdahl
European Journal of Clinical Investigation|July 1, 1996
Growth hormone, insulin-like growth factors and bone remodellingE F Eriksen, M Kassem, B Langdahl
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 19, 2019
Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosisA S Koldkjær Sølling, T Harsløf, B Langdahl
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 24, 2019
Glucagon-like peptide-1 receptor agonists and fracture risk-limitations to current knowledgeK Hygum, T Harsløf, B Langdahl, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 26, 2022
Incident peptic ulcers and concomitant treatment of direct oral anticoagulants and oral bisphosphonates-a real-world cohort studyJ Starup-Linde, B Langdahl, P Vestergaard, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|January 31, 2021
The predictive value of bone turnover markers during discontinuation of alendronate: the PROSA studyA S Sølling, T Harsløf, N H Bruun, et al.
Kidney International|September 1, 1999
Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failureM Rix, H Andreassen, P Eskildsen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 15, 1999
Hormone replacement therapy prevents osteoclastic hyperactivity: A histomorphometric study in early postmenopausal womenE F Eriksen, B Langdahl, A Vesterby, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|April 22, 2016
Hypercalcemia after discontinuation of long-term denosumab treatmentA S Koldkjær Sølling, T Harsløf, A Kaal, et al.
Pageof 3